Contribute Try STAT+ Today

This September marked the third anniversary of a pivotal moment in biotech. Back in 2016, Sarepta Therapeutics convinced the Food and Drug Administration to approve a treatment for Duchenne muscular dystrophy based on preliminary evidence from a tiny clinical trial.

Critics — and there were many — argued that Sarepta hadn’t done enough to prove that its drug could actually help patients. And there were countless tweets and editorials claiming that the FDA had set a dangerous precedent by approving the company’s medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy